Medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (INN) or norephedrine or their salts: for therapeutic or prophylactic uses, (not packaged for retail sale)

In 2024, medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (inn) or norephedrine or their salts: for therapeutic or prophylactic uses, (not packaged for retail sale) trade exhibited modest growth, with global flows reaching $130,719,126 and a three-year compound annual growth rate of -3.7% (five-year: +4.8%). The all-time peak of $314,248,620 was recorded in 2018; the current level is 58% below that high-water mark.

Over the 30-year observation window (1995–2024), 62% of years recorded positive growth, indicating a mildly upward trajectory with periodic contractions. Trend momentum is decelerating (-4.6% acceleration).

The supply side is moderately concentrated (Herfindahl-Hirschman Index 0.154). The three largest exporters — Ireland ($40.2M), United States ($32.2M), and Germany ($28.0M) — collectively dominate supply flows. The leading exporter has grown at +83.2% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.060). The three largest import markets are France ($19.7M), Malaysia ($12.5M), and Vietnam ($10.5M). The largest importing market sources from 9 different supplying countries.

The dominant trade corridor is United States → France at $19.0M, representing 96.8% of the importer's total demand.

The volatility score for medicaments: containing alkaloids or their derivatives: other than ephedrine, pseudoephedrine (inn) or norephedrine or their salts: for therapeutic or prophylactic uses, (not packaged for retail sale) is 22 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, modest but steady demand provides a reasonable entry window. A moderately concentrated market rewards differentiated positioning and strategic partner selection.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.